Bafna Pharmaceuticals share news and announcements
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.95.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,048 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 134.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 10.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,422
Bafna Pharmaceuticals share news and announcements
637 announcements, routine notices left out, newest first. Page 7 of 13.
Aug 2017
9 Aug · Legal
Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 08-Aug-2017, regarding " Outcome of Board Meeting held on August 08, 2017.On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is awaited.8 Aug · Board meeting
Jul 2017
21 Jul · Results
14 Jul · Shareholding for the Period Ended June 30, 2017
Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click ....
Jun 2017
5 Jun · Declaration Of Unmodified Opinion
5 Jun · Declaration for audit reports with unmodified opinion(s)
May 2017
27 May · Board meeting
Apr 2017
30 Apr · Certificate Under Regulation 40 For The Year Ended 31St March, 2017
26 Apr · Compliance Certificate For The Year Ended 31St March, 2017
20 Apr · Shareholding for the Period Ended March 31, 2017
Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click ....
Mar 2017
18 Mar · Outcome of Committee Meeting
14 Mar · Board meeting
Feb 2017
13 Feb · Results
Details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....
Jan 2017
24 Jan · Meeting
20 Jan · Corrigendum
20 Jan · Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
19 Jan · Shareholding for the Period Ended December 31, 2016
Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click ....11 Jan · Meeting